Impact of hydroxyurea on clinical events in the BABY HUG trial
Open Access
- 22 November 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 120 (22) , 4304-4310
Abstract
The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninety-three subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials.gov).Keywords
This publication has 38 references indexed in Scilit:
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Increase in Invasive Streptococcus Pneumoniae Infections in Children with Sickle Cell Disease since Pneumococcal Conjugate Vaccine LicensureThe Journal of Pediatrics, 2011
- Recruitment of infants with sickle cell anemia to a Phase III trial: Data from the BABY HUG studyContemporary Clinical Trials, 2010
- Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilizationAmerican Journal of Hematology, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Adherence to study medication and visits: Data from the BABY HUG trialPediatric Blood & Cancer, 2009
- Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trialPediatric Blood & Cancer, 2009
- The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study designPediatric Blood & Cancer, 2009
- Vaso‐occlusive painful events in sickle cell disease: Impact on child well‐beingPediatric Blood & Cancer, 2009
- Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful eventsBritish Journal of Haematology, 2009